Table 1.
Demographic and HIV-related Characteristics among REACH and PACTG 219/219C Participants with Liver Function Tests (LFTs) between age 15 and 20 years
| Cohort |
|||||
|---|---|---|---|---|---|
| Characteristic | Total (N=1785) |
(A) REACH: HIV uninfected (N=173) |
(B) REACH: Behaviorally HIV-infected (N=319) |
(C) 219/219C: Behaviorally HIV-infected (N=251) |
(D) 219/219C: Perinatally HIV-infected (N=1042) |
| Age at LFT (median, IQR) | 17.3 (16.1, 18.8) | 17.6 (16.5, 18.2) | 17.9 (17.0, 18.5) | 17.9 (15.8, 19.5) | 17.1 (16.0, 19.0) |
| Number with at least 2 LFTs | 1307 | 38 | 282 | 192 | 795 |
| Follow-up time (median, IQR) | 2.01 (1.08, 3.04) | 1.38 (1.00, 2.03) | 1.99 (1.09, 2.84) | 1.93 (1.00, 3.00) | 2.09 (1.12, 3.55) |
| Female sex | 1,055 (59%) | 135 (78%) | 242 (76%) | 146 (58%) | 532 (51%) |
| Race/Ethnicity | |||||
| White Non-Hispanic | 227 (13%) | 12 (7%) | 10 (3%) | 57 (23%) | 148 (14%) |
| Black Non-Hispanic | 1,019 (57%) | 106 (61%) | 231 (72%) | 130 (52%) | 552 (53%) |
| Other Non-Hispanic | 50 (3%) | 12 (7%) | 19 (6%) | 6 (2%) | 13 (1%) |
| Hispanic | 488 (27%) | 43 (25%) | 58 (18%) | 58 (23%) | 329 (32%) |
| BMI Z-score, mean (SD) | 0.41 (1.17) | 0.66 (1.19) | 0.74 (1.08) | 0.39 (1.23) | 0.27 (1.16) |
| Liver Biomarker Measures | |||||
| FIB-4 Score > 1.45 | 40 (2%) | 2 (1%) | 2 (1%) | 7 (3%) | 29 (3%) |
| FIB-4 Score > 3.25 | 9 (1%) | 0 (0%) | 1 (<1%) | 1 (<1%) | 7 (1%) |
| APRI score > 0.5 | 209 (12%) | 6 (3%) | 21 (7%) | 39 (16%) | 143 (14%) |
| APRI score > 1.5 | 37 (2%) | 2 (1%) | 2 (1%) | 7 (3%) | 26 (2%) |
| HIV Disease Severity measures and Characteristics among HIV-infected participants | |||||
| ARV regimen type | |||||
| HAART w/PI | 744 (46%) | --- | 60 (19%) | 66 (26%) | 618 (59%) |
| HAART w/out PI | 170 (11%) | --- | 16 (5%) | 60 (24%) | 94 (9%) |
| Non-HAART ARV | 258 (16%) | --- | 82 (26%) | 28 (11%) | 148 (14%) |
| Not on ARVs | 440 (27%) | --- | 161 (50%) | 97 (39%) | 182 (17%) |
| Current didanosine use | 225 (14%) | --- | 12 (4%) | 25 (10%) | 188 (18%) |
| Current stavudine use | 342 (21%) | --- | 16 (5%) | 43 (17%) | 283 (27%) |
| Viral load (copies/mL) | |||||
| ≤ 400 | 545 (34%) | --- | 75 (24%) | 80 (32%) | 390 (37%) |
| 401 - <1000 | 94 (6%) | --- | 22 (7%) | 8 (3%) | 64 (6%) |
| 1,000 - <10,000 | 348 (22%) | --- | 115 (36%) | 42 (17%) | 191 (18%) |
| 10,000 or greater | 442 (27%) | --- | 106 (33%) | 57 (23%) | 279 (27%) |
| CD4 count (cells/mm3) | |||||
| Median (IQR) | 483 (292, 702) | --- | 487 (365, 667) | 474 (283, 652) | 483 (266, 726) |
| <200 | 251 (16%) | --- | 28 (9%) | 37 (15%) | 186 (18%) |
| 200 - <350 | 253 (16%) | --- | 49 (15%) | 46 (18%) | 158 (15%) |
| 350 - <500 | 310 (19%) | --- | 90 (28%) | 52 (21%) | 168 (16%) |
| 500 or greater | 747 (47%) | --- | 152 (48%) | 112 (44%) | 483 (46%) |
IQR=interquartile range (expressed as 25th percentile, 75th percentile); SD=standard deviation, BMI=body mass index; LFT=liver function test; ARV=antiretroviral; HAART=highly active antiretroviral therapy (at least 3 drugs from at least 2 ARV drug classes); PI=protease inhibitor.
Characteristics reflected status at earliest measurement within age 15–20 years for REACH and 219C behaviorally HIV-infected cohorts and latest measures within age 15–20 years for 219C perinatally HIV-infected participants. Measurements or characteristics were unavailable for some participants, including race/ethnicity (n=1), BMI z-score (n=102), viral load (n=183), and CD4 count (n=51).